Navigation Links
Excalibur - 'Transforming' Biotech Deals can Still be Achieved
Date:10/1/2008

LONDON, October 1 /PRNewswire/ -- Excalibur, the international investment house specialising in medical sciences, said today 'transforming' deals could still be achieved in the UK biotech sector despite the most severe market conditions.

Excalibur, founded by Professor Sir Christopher Evans and a development of Merlin Biosciences, was instrumental in securing important funding to enable York Pharma plc, the specialist dermatology company, to make a significant product acquisition which will propel the company into profit and generate significant revenues.

Following York Pharma's announcement today (Wednesday) that it has completed the EUR28.5 million financing package to fund the acquisition, Professor Sir Christopher Evans, chairman of Excalibur, said: "This is exactly what everyone wants to see in the UK biotech sector, where a loss-making company can be turned into a revenue generating and profitable operation offering products to the market.

"Excalibur was delighted to assist York Pharma through an investment by Merlin Biosciences Fund III while the company secured additional funding from the United States. While it is extremely reassuring that investment funding is still available from the USA, it is important in the UK biotech sector to show that such transforming deals can be achieved despite the grim economic picture."

York Pharma has acquired the sales and worldwide commercial rights to two dermatological/wound care products, Flammazine and Flammacerium, from Solvay Pharmaceuticals. The products are sold in 21 countries and are used in the prevention and treatment of infections in burn wounds and tropical wounds. The products generate annual revenues of GBP8.5 million.

Sir Christopher commented: "Last year York Pharma acquired a Merlin Biosciences Fund III company, Derms Developments, which gave it a sales, marketing and product offering. This deal now means the company can take another important step forward and we're sure that York will go from strength to strength and we are pleased to see it send out a strong signal to the biotech industry."

Notes to Editors

About Excalibur

Excalibur was launched in April this year and operates across the entire medical sciences sector. It has adopted the successful investment strategy of Merlin's Fund III which has focused more broadly on healthcare and medical science investments and is already delivering significant returns to investors with four more years to run.

Further information: Ramsay Smith, Media House International. Tel: +44(0)207-397-8460/+44(0)7788-414856. Email: ramsay@mediahouse.co.uk


'/>"/>
SOURCE Excalibur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Excalibur Celebrates PIramed Sale With Substantial Cash Return to Investors
2. SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID
3. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
4. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
5. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
6. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
7. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
8. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
9. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
10. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
11. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):